Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients
- 주제(키워드) Acute myeloid leukemia , Core binding factor , Genome-wide single nucleotide polymorphism array
- 주제(기타) Hematology
- 설명문(일반) [Park, Silvia; Jung, Chul Won] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 135710, South Korea; [Choi, Hangseok] Chung Ang Univ, Coll Pharm, Seoul, South Korea; [Kim, Hee Je] Catholic Univ Korea, Dept Hematol, Seoul, South Korea; [Ahn, Jae-Sook; Kim, Hyeoung-Joon] Chonnam Natl Univ, Hwasun Hosp, Hematol Oncol, Gwangju, Jeollanam Do, South Korea; [Kim, Hyeoung-Joon] Chonnam Natl Univ, Genom Res Ctr Hematopoiet Dis, Hwasun Hosp, Gwangju, Jeollanam Do, South Korea; [Kim, Sung-Hyun] Dong A Univ, Dept Hematol Oncol, Coll Med, Busan, South Korea; [Mun, Yeung-Chul] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol,Sch Med, 610 Univ Ave, Toronto, ON M5G 2M9, Canada; [Kim, Dennis (Dong Hwan)] Ewha Womans Univ, Dept Hematol Oncol, Coll Med, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 SPRINGER
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000160009
- 본문언어 영어
- Published As http://dx.doi.org/10.1007/s00277-018-3260-6
초록/요약
The present study attempted to build a single nucleotide polymorphism (SNP)-based risk model for predicting overall survival (OS) and event-free survival (EFS) in patients with core binding factor acute myeloid leukemia (CBF-AML). Adopting genome-wide SNP array using Affymetrix SNP array 6.0, we analyzed 868,157 SNPs with respect to OS and EFS in 104 patients with CBF-AML. Significant SNPs were identified from single SNP analysis. The risk model was constructed with incorporation of six SNPs and three clinical factors (age, c-kit exon 17 mutation, and LDH) for OS and six SNPs and three clinical factors (age, WBC, and LDH) for EFS. The model was further defined into low- and high-risk groups based on risk scores. The median age was 39 years, and the subgroup of t(8;21) and inv(16) or t(16;16) was assessed in 68 (65.4%) and 36 patients (34.6%). Finally, six SNPs per each OS (rs4353685, rs4908185, rs7709207, rs12034, rs1554844, and rs17241868) and EFS (rs13385610, rs11210617, rs11169282, rs7709207, rs4438401, and rs16894846) were incorporated into the risk model. OS was significantly different in favor of the low risk group (80.4 +/- 8.4%) compared to the high-risk group (22.0 +/- 7.3% at 3 years; p = 8.75 x 10(- 13); HR 8.67). For EFS, there was also a significant difference between the low- (75.0 +/- 5.8%) versus high-risk group (17.1 +/- 6.3% at 3 years; p = 5.95 x 10(- 13); HR 7.67). A genome-wide SNP-based risk model can stratify CBF-AML patients according to their OS and EFS in 104 patients.
more